A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Trial Profile

A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Active, no longer recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms CheckMate 374
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 15 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 23 Sep 2016 Planned End Date changed from 1 Oct 2021 to 1 Dec 2021.
    • 11 Jul 2016 Planned End Date changed from 1 Oct 2017 to 1 Oct 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top